AbbVie has petitioned the Supreme Court (SCOTUS) to review a U.S. appeals court decision that could erode attorney-client privilege in corporate settings. The pharmaceutical company argues that the lower court's ruling, which allows the filing of a sham patent-infringement lawsuit to overcome attorney-client privilege, threatens to expose sensitive corporate communications. AbbVie is seeking to protect its records related to the AndroGel lawsuit. The case highlights the ongoing legal battles surrounding patent and corporate law, as companies strive to maintain confidentiality in their legal communications.